For example, the literature supports that inhibition of janus kinase 1 (JAK1) improves inflammatory bowel disease [7]; JAK1/3 inhibitors are a therapeutic modality for ankylosing spondylitis [5]. This evidence concerns the gene JAK1 and ankylosing spondylitis.